TriSalus Life Sciences Inc
NASDAQ:TLSI
Net Margin
TriSalus Life Sciences Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
T
|
TriSalus Life Sciences Inc
NASDAQ:TLSI
|
172.8m USD |
-95%
|
|
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
633.6T EUR | N/A | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
169.7B USD |
5%
|
|
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
100.1B USD |
9%
|
|
| US |
|
World Financial Holding Group
OTC:WFHG
|
6.6B USD | N/A | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
86.4B Zac |
69%
|
|
| US |
|
Coupang Inc
F:788
|
43.7B EUR |
1%
|
|
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
48.8B USD |
-44%
|
|
| US |
R
|
Reddit Inc
NYSE:RDDT
|
46.1B USD |
13%
|
|
| ID |
|
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
619.3T IDR |
1%
|
|
| CH |
G
|
Galderma Group AG
SIX:GALD
|
31.3B CHF |
8%
|
TriSalus Life Sciences Inc
Glance View
TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on TriSalus Life Sciences Inc's most recent financial statements, the company has Net Margin of -95%.
You don't have any saved screeners yet